Aimmune Therapeutics (NASDAQ:AIMT) released its quarterly earnings results on Thursday. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($1.06), MarketWatch Earnings reports.
AIMT stock opened at $13.21 on Friday. Aimmune Therapeutics has a 52 week low of $10.09 and a 52 week high of $37.00. The company has a fifty day simple moving average of $16.60 and a two-hundred day simple moving average of $19.93. The company has a current ratio of 8.10, a quick ratio of 8.01 and a debt-to-equity ratio of 0.59.
Several research analysts have issued reports on AIMT shares. Zacks Investment Research cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 27th. Wedbush restated a “buy” rating and set a $66.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, May 13th. BidaskClub downgraded Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 10th. HC Wainwright lowered their price target on Aimmune Therapeutics from $30.00 to $15.00 and set a “neutral” rating on the stock in a report on Tuesday, May 12th. Finally, Cantor Fitzgerald cut their price objective on shares of Aimmune Therapeutics from $32.00 to $24.00 in a report on Friday. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company. Aimmune Therapeutics presently has an average rating of “Hold” and a consensus target price of $37.00.
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Further Reading: Net Margin
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.